Financial reports
ARS
2023 FY
Annual report to shareholders
24 Apr 24
10-K
2023 FY
Annual report
20 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
ARS
2022 FY
Annual report to shareholders
12 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
12 Mar 24
8-K
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023
20 Feb 24
8-K
Other Events
23 Jan 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
8-K
Other Events
16 Jan 24
8-K
Other Events
12 Jan 24
8-K
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
4 Dec 23
8-K
Entry into a Material Definitive Agreement
17 Nov 23
8-K
IDEAYA Biosciences, Inc. Reports Third Quarter 2023
7 Nov 23
8-K
Other Events
27 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
20 Feb 24
424B5
Prospectus supplement for primary offering
19 Jan 24
424B5
Prospectus supplement for primary offering
25 Oct 23
424B5
Prospectus supplement for primary offering
24 Oct 23
424B5
Prospectus supplement for primary offering
26 Jun 23
S-3ASR
Automatic shelf registration
26 Jun 23
424B5
Prospectus supplement for primary offering
25 Apr 23
424B5
Prospectus supplement for primary offering
24 Apr 23
S-8
Registration of securities for employees
7 Mar 23
424B5
Prospectus supplement for primary offering
15 Sep 22
Proxies
DEF 14A
Definitive proxy
19 Apr 24
DEF 14A
Definitive proxy
14 Apr 23
DEF 14A
Definitive proxy
26 Apr 22
DEF 14A
Definitive proxy
19 Apr 21
DEF 14A
Definitive proxy
27 Apr 20
Other
EFFECT
Notice of effectiveness
21 Apr 21
CORRESP
Correspondence with SEC
16 Apr 21
UPLOAD
Letter from SEC
25 Mar 21
SEC STAFF
SEC staff action: Order
23 Mar 21
SEC STAFF
SEC staff action: Order
23 Feb 21
EFFECT
Notice of effectiveness
11 Jun 20
CORRESP
Correspondence with SEC
9 Jun 20
UPLOAD
Letter from SEC
8 Jun 20
CT ORDER
Confidential treatment order
24 May 19
EFFECT
Notice of effectiveness
23 May 19
Ownership
4
Yujiro S Hata
4 Mar 24
4
Briseno Andres Ruiz
4 Mar 24
4
Darrin Beaupre
4 Mar 24
4
MICHAEL ANTHONY WHITE
4 Mar 24
4
Jason Throne
4 Mar 24
SC 13G
JANUS HENDERSON GROUP PLC
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Avidity Partners Management LP
14 Feb 24
SC 13G/A
Logos Global Management LP
13 Feb 24